ArcherDX launches B Cell Receptor Sequencing Assays for Immune Repertoire Characterization at Immunology 2017

BOULDER, Colo., May 15, 2017 /PRNewswire/ -- ArcherDX, the leader in NGS-based fusion assays, today announced the release of Archer^® Immunoverse™ B Cell Receptor (BCR) assays to characterize the human B cell repertoire. These assays expand the cadre of Archer immune repertoire sequencing assays and complements the Immunoverse T Cell Receptor assays that were launched last year. ArcherDX announced these B cell repertoire-sequencing assays at Immunology 2017, the annual global immunology conference that began this weekend in Washington, DC. 

Immunoverse BCR kits are targeted NGS assays that utilize patented Anchored Multiplex PCR (AMP™) chemistry for open-ended amplification with molecular-barcoded (MBC) adapters. These adapters are ligated to RNA prior to amplification, enabling post-sequencing deduplication and error correction. "Recent publications have demonstrated that primer bias from opposing primer-based enrichment can result in a gross misrepresentation of clonal frequencies," said Jason Myers, Ph.D., CEO of ArcherDX. "Our AMP-based approach more accurately represents the immune repertoire by using molecular barcode-based deduplication to eliminate PCR bias."

Once libraries are sequenced, Archer Analysis reports isotype and subclass information for all detected clonotypes along with the somatic hypermutation status for the most frequent clones. "Our BCR assay allows us to identify and report IGHV mutation status, which is critical for researchers studying chronic lymphocytic leukemia," stated Brian Kudlow, Ph.D., Vice President of Research and Development at ArcherDX.

Immunoverse BCR assays include kits for IGH, IGK, and IGL that are provided in 8-reaction kits that use lyophilized reagents to minimize user error, contamination and hands-on time. Flexible input requirements from as little as 25ng RNA from PBMC, FFPE or fresh frozen tissue make this assay suitable for a wide range of applications.

Learn more at archerdx.com/immunoverse.

About ArcherDX

ArcherDX addresses the bottlenecks associated with using NGS in oncogenic mutation detection by offering a robust platform for targeted sequencing. By combining proprietary AMP™ chemistry with easy-to-use, lyophilized reagents, Archer NGS assays generate highly enriched sequencing libraries to detect gene fusions, point mutations, CNVs and RNA abundance. Archer product lines focus on specific disease states and input types, including VariantPlex™ and FusionPlex® assays for SNV/indel, copy number variation (CNV) and gene fusion detection from solid tumors, sarcomas and blood cancers; Reveal ctDNA™ 28 assay for mutation detection from liquid biopsies; and Immunoverse assays for immune repertoire characterization.

Complemented by powerful bioinformatics software, ArcherDX technology dramatically enhances complex mutation identification and discovery.  

ArcherDX is headquartered in Boulder, Colorado.  

Archer^®, FusionPlex^®, VariantPlex®, Immunoverse™, Reveal ctDNA™ and AMP™ are trademarks of ArcherDX, Inc.

Contacts:
ArcherDX, Inc.
Jason Amsbaugh
+1 303 357 9001
[email protected]

SOURCE ArcherDX

Related Links

http://www.archerdx.com